Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Net Loss Per Common Share, Disclosure: Schedule of Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2016

	For the year ended December 31,
	2016		2015
Net loss from continuing operations	$	(337,179)	$	(2,982,920)
Net income (loss) from discontinued operations		1,197		(371,307)
Net loss		(335,982)		(3,354,227)
Basic and diluted:
Preferred stock cumulative dividend - Series D		(43,058)		(42,942)
Income applicable to preferred stockholders		(43,058)		(42,942)
Net loss applicable to common stockholders	$	(379,040)	$	(3,397,169)